This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

AcutePreventiveSafetyDosingDosingDosingMOASavings & SupportSavings
& SupportSavings & SupportFormulary CoverageResourcesResourcesProvider & Patient EducationPrior Authorization
Prescribing InformationIndicationsPatient InformationPatient Site
Resources for Prescribing Nurtec ODTResources for Prescribing Nurtec ODTPrior authorization resourcesTools and resources to support the prior authorization processTools and resources to support the prior authorization process Migraine coding resource A helpful overview of accessibility for preventive treatment, example International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes to use, and more best practices when prescribing Nurtec ODT to your patients with episodic migraine.1 View Loading Email Loading Sample letter of appeal

A sample to help simplify writing a letter of appeal.

 View Loading Email Loading Sample letter of medical necessity

A sample to help simplify writing a letter of medical necessity.

 View Loading Email Loading Specialist consultation referral

A form for referring a patient to another healthcare professional.

 View Loading Email Loading Letter of medical necessity considerations

A guide to help you write a letter of medical necessity.

 View Loading Email Loading Letter of appeal
considerations

A guide to help you write a letter of appeal.

 View Loading Email Loading Prior and reauthorization worksheet

A tool to help you prepare your PA requests for appropriate patients with their eligibility criteria per the health plan to approve initial or continued use of Nurtec ODT.

 View Loading Email LoadingReference:Nurtec ODT. Package insert. Pfizer Inc. Have samples of Nurtec ODT delivered to your office Get samples Loading Get the details on savings and support Get savings information Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-NNT-USA-4379
INDICATIONSNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.
Important Safety Information Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted. Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.If signs or symptoms of Raynaud’s phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%). Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp. Use in Specific Populations: Pregnancy: It is not known if Nurtec ODT can harm an unborn baby.
Lactation: The transfer of rimegepant into breast milk is low (<1%). Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.IndicationsNurtec ODT is indicated in adults for the:
  • acute treatment of migraine with or without aura
  • preventive treatment of episodic migraine

Please click here for full Prescribing Information.